These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7028460)

  • 1. Degradation of pork insulin and biosynthetic human insulin in vitro and in vivo: a comparative study.
    Halban PA; Duckworth WC
    Endocr Res Commun; 1981; 8(2):127-34. PubMed ID: 7028460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic activity and pharmacokinetics of biosynthetic human insulin in the rat.
    Halban PA; Berger M; Gjinovci A; Renold AE
    Diabetes Care; 1981; 4(2):238-43. PubMed ID: 7011735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosynthetic human insulin: pharmacokinetics and effects in healthy human volunteers.
    Brogard JM; Blickle JF; Pinget M; Stahl A; Dorner M
    Int J Clin Pharmacol Ther Toxicol; 1983 Nov; 21(11):575-80. PubMed ID: 6360919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [125I]-insulin metabolism by the rat liver in vivo: evidence that a neutral thiol-protease mediates rapid intracellular insulin degradation.
    Williams FG; Johnson DE; Bauer GE
    Metabolism; 1990 Mar; 39(3):231-41. PubMed ID: 2407925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human insulin prepared by recombinant DNA techniques and native human insulin interact identically with insulin receptors.
    Keefer LM; Piron MA; De Meyts P
    Proc Natl Acad Sci U S A; 1981 Mar; 78(3):1391-5. PubMed ID: 7015337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potency of biosynthetic human insulin determined in vitro.
    Fussgaenger RD; Ditschuneit HH; Martini H; Wiebauer-De Lenardis H; Etzrodt H; Thun C; Ditschuneit H; Pfeiffer EF; Enzmann F
    Diabetes Care; 1981; 4(2):228-34. PubMed ID: 7011733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor binding properties and biologic activity in vitro of biosynthetic human insulin.
    Keefer LM; Piron MA; De Meyts P
    Diabetes Care; 1981; 4(2):209-14. PubMed ID: 7011729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of biosynthetic human insulin to human antibodies and receptors.
    Petersen KG; Schlüter K; Steinhilber S; Kerp L
    Diabetes Care; 1981; 4(2):248-9. PubMed ID: 7011737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological properties of an initial degradation product of insulin by insulin-degrading enzyme.
    Yonezawa K; Yokono K; Shii K; Hari J; Yaso S; Sakamoto T; Kawase Y; Akiyama H; Taketomi S; Baba S
    Endocrinology; 1989 Jan; 124(1):496-504. PubMed ID: 2642422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial site of insulin cleavage by insulin protease.
    Duckworth WC; Stentz FB; Heinemann M; Kitabchi AE
    Proc Natl Acad Sci U S A; 1979 Feb; 76(2):635-9. PubMed ID: 284388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin binding, biologic activity, and metabolism of biosynthetic human insulin.
    Olefsky JM
    Diabetes Care; 1981; 4(2):244-7. PubMed ID: 7011736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of a mutant insulin by a receptor-mediated process and an insulin degrading enzyme.
    Kobayashi M; Iwasaki M; Watanabe N; Ishibashi O; Takata Y; Haruta T; Sasaoka T; Shigeta Y; Inouye K
    Diabetes Res Clin Pract; 1986; 2(5):257-62. PubMed ID: 3536368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biosynthetic human insulin: effect in healthy men on plasma glucose and non-esterified fatty acids in comparison with highly purified pork insulin.
    Viberti GC; Pickup JC; Keen H; Bilous RW; Mattock M; Jarrett RJ; Glynne A; Rogers R
    Diabetes Care; 1981; 4(2):175-9. PubMed ID: 7011721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Internalization of 125I-insulin by IM-9 cultured human lymphocytes: a comparison between A14-monoiodo-pork and biosynthetic human insulin.
    Carpentier JL; Halban PA; Renold AE; Orci L
    Diabetes Care; 1981; 4(2):220-2. PubMed ID: 7011731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor binding and effect of biosynthetic human insulin on 2-deoxyglucose transport.
    Wieringa T; van Putten JP; Van Dijk-Besling M; Krans HM
    Diabetes Care; 1981; 4(2):254-6. PubMed ID: 7011740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human insulin.
    Raptis S; Dimitriadis G
    Clin Physiol Biochem; 1985; 3(1):29-42. PubMed ID: 3888492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Degradation of insulin by insulin-degrading enzyme and biological characteristics of its fragments.
    Yonezawa K; Yokono K; Yaso S; Hari J; Amano K; Kawase Y; Sakamoto T; Shii K; Imamura Y; Baba S
    Endocrinology; 1986 May; 118(5):1989-96. PubMed ID: 3516656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biosynthetic human insulin. Pharmacokinetic characteristics and activity in normal subjects].
    Brogard JM; Blickle JF; Stahl A; Pinget M; Dorner M
    Presse Med; 1984 Feb; 13(5):265-8. PubMed ID: 6229776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of insulin domains important for binding to and degradation by endosomal acidic insulinase.
    Authier F; Danielsen GM; Kouach M; Briand G; Chauvet G
    Endocrinology; 2001 Jan; 142(1):276-89. PubMed ID: 11145591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical, physical, and biologic properties of biosynthetic human insulin.
    Chance RE; Kroeff EP; Hoffmann JA; Frank BH
    Diabetes Care; 1981; 4(2):147-54. PubMed ID: 7011716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.